- Home
- EFR vs SCLXW Comparison
EFR vs SCLXW Comparison
Compare EFR & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EFR
- SCLXW
- Stock Information
- Founded
- EFR 2003
- SCLXW N/A
- Country
- EFR United States
- SCLXW United States
- Employees
- EFR N/A
- SCLXW 117
- Industry
- EFR Trusts Except Educational Religious and Charitable
- SCLXW Biotechnology: Pharmaceutical Preparations
- Sector
- EFR Finance
- SCLXW Health Care
- Exchange
- EFR Nasdaq
- SCLXW Nasdaq
- Market Cap
- EFR N/A
- SCLXW N/A
- IPO Year
- EFR N/A
- SCLXW N/A
- Fundamental
- Price
- EFR $11.09
- SCLXW $0.11
- Analyst Decision
- EFR
- SCLXW
- Analyst Count
- EFR 0
- SCLXW 0
- Target Price
- EFR N/A
- SCLXW N/A
- AVG Volume (30 Days)
- EFR 88.6K
- SCLXW 4.0K
- Earning Date
- EFR 01-01-0001
- SCLXW 03-07-2025
- Dividend Yield
- EFR 9.43%
- SCLXW N/A
- EPS Growth
- EFR N/A
- SCLXW N/A
- EPS
- EFR 1.69
- SCLXW N/A
- Revenue
- EFR N/A
- SCLXW $55,152,000.00
- Revenue This Year
- EFR N/A
- SCLXW N/A
- Revenue Next Year
- EFR N/A
- SCLXW N/A
- P/E Ratio
- EFR $7.74
- SCLXW N/A
- Revenue Growth
- EFR N/A
- SCLXW 22.02
- 52 Week Low
- EFR $10.95
- SCLXW $0.18
- 52 Week High
- EFR $13.29
- SCLXW $0.18
- Technical
- Relative Strength Index (RSI)
- EFR 11.61
- SCLXW N/A
- Support Level
- EFR $12.15
- SCLXW N/A
- Resistance Level
- EFR $12.30
- SCLXW N/A
- Average True Range (ATR)
- EFR 0.11
- SCLXW 0.00
- MACD
- EFR -0.04
- SCLXW 0.00
- Stochastic Oscillator
- EFR 0.55
- SCLXW 0.00
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.